Barclays PLC Purchases 182,315 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Barclays PLC lifted its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 312.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 240,615 shares of the company’s stock after acquiring an additional 182,315 shares during the quarter. Barclays PLC’s holdings in Lyell Immunopharma were worth $332,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Centiva Capital LP bought a new stake in shares of Lyell Immunopharma in the 3rd quarter worth $31,000. Intech Investment Management LLC bought a new stake in shares of Lyell Immunopharma in the 3rd quarter worth $52,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Lyell Immunopharma in the 3rd quarter worth $52,000. Dimensional Fund Advisors LP grew its position in Lyell Immunopharma by 197.8% during the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after buying an additional 26,635 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Lyell Immunopharma by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock worth $68,000 after buying an additional 19,287 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $0.70 on Friday. Lyell Immunopharma, Inc. has a 52-week low of $0.58 and a 52-week high of $3.26. The company has a 50-day simple moving average of $0.90 and a 200 day simple moving average of $1.25. The company has a market capitalization of $203.90 million, a PE ratio of -0.88 and a beta of -0.45.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. The firm had revenue of $0.03 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

LYEL has been the subject of a number of research analyst reports. Bank of America downgraded shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and decreased their price objective for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 12th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.